Frost & Sullivan: User-friendly and Superior Patient Monitoring Devices to Drive the Continuous Glucose Monitoring Market in Europe

LONDON, June 16, 2010 - The continuous glucose monitoring (CGM) market is in its development
stage. The primary factor leading to the growth of the (CGM) market in Europe
is the need for an easy-to-use and patient-friendly glucose-monitoring
device. The traditional method of monitoring glucose was difficult and
inconvenient for patients. The CGM method is not only hassle-free, but also
gives a better diagnosis of diabetes.

    (Logo: photos.prnewswire.com/prnh/20081117/FSLOGO)
    (Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan
(www.patientmonitoring.frost.com), European Market for Continuous
Glucose Monitoring, finds that the market earned revenues of $23.5 million in
2009 and estimates this to reach $52.0 million in 2016. The markets covered
by region in this research service are Benelux, Germany, France, Italy,
Scandinavia, Spain and the United Kingdom.

"The most important driver of the CGM market in Europe the market is the
requirement of a convenient, patient-friendly, and affordable device that
facilitates superior therapy management for diabetes," says Frost & Sullivan
Senior Research Analyst Akanksha Joshi.

An increase in the aging population in the western European region has
resulted in the higher incidence of fatal diseases such as cardiovascular
diseases, diabetes and stroke, spurring the need for regular monitoring of
the glucose levels of patients. Therefore, pioneering technology in the
product line at considerably lower rates is sought after by the medical
community to help in proper therapy management for diabetes, prevent the
occurrence of cardiovascular disorder, reduce patient stay in hospital and
lower the costs incurred by patients.

However, CGM is not reimbursed and the per sensor cost is steep. This
restrains patients from purchasing the devices.

"The traditional finger-stick method offers glucose monitoring solution
at much lower rates and is reimbursed all across Europe," explains Joshi. "On
the other hand, while using a CGM the patient has to buy a starter kit and
pay for the disposable sensors year-on-year, making the method of treatment
more expensive."

Nonetheless, collaboration with established local companies will help
manufacturers to provide effective services and, at the same time, maintain
profit margins. Integration of continuous glucose monitors with insulin pumps
will pave way for reimbursement options for manufactures, thus reducing the
total cost incurred by patients.

"To enable the market participants to include such systems in the
reimbursable category, significant clinical evidence suggesting that the
device is essential for the patient's well-being is required," concludes
Joshi. "Moreover, when CGM is integrated with insulin pumps, the product will
become reimbursable as it is likely to fall under the medically essential
classification of insurance agencies."

If you are interested in more information on Frost & Sullivan's research
on the European Market for Continuous Glucose Monitoring, please send an
e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com,
with your full name, company name, title, telephone number, company e-mail
address, company website, city, state and country.

European Market for Continuous Glucose Monitoring is part of the Patient
Monitoring Growth Partnership Services programme, which also includes
research in the following markets: European Market for Ventilation and Airway
Management Devices, European Markets for Disease Management, European
Telemetry Equipment Market, and European Market for Multiparameter midrange
Patient Monitors. All research services included in subscriptions provide
detailed market opportunities and industry trends that have been evaluated
following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best-in-class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best-practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 40 offices on six continents. To join our Growth Partnership,
please visit www.frost.com.

    European Market for Continuous Glucose Monitoring
    M569

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49-(0)-69-7703343
    E: katja.feick@frost.com
    www.frost.com
    Twitter: twitter.com/frost_sullivan

Katja Feick, Corporate Communications - Europe, Frost & Sullivan, +49-(0)-69-7703343, katja.feick at frost.com